boosted protease inhibitors + maraviroc

Boosted protease inhibitors plus maraviroc is a combination antiretroviral therapy used in the treatment of HIV-1 infection. This regimen combines two distinct drug classes with different mechanisms of action: 1. **Maraviroc (MVC)** is a CCR5 antagonist that prevents HIV from entering uninfected cells by blocking the CCR5 receptor on the surface of immune cells, which is the predominant route of entry for CCR5-tropic HIV-1[5]. 2. **Boosted protease inhibitors (PI/r)** are HIV protease inhibitors administered with a low dose of ritonavir (the "booster") to inhibit the CYP3A4 enzyme, which increases the plasma concentration and half-life of the primary protease inhibitor. This combination has been studied extensively in treatment-experienced patients, particularly those with adverse effects from previous regimens or those requiring simplification of their treatment. When used together, maraviroc dosing must be adjusted (typically to 150mg twice daily) when combined with most boosted protease inhibitors due to drug interactions[5][6].

Other names

PI/r + maravirocboosted PI + maravirocmaraviroc + boosted protease inhibitors